UA-45667900-1
Showing posts with label ARFID. Show all posts
Showing posts with label ARFID. Show all posts

Sunday, 5 July 2026

Overcoming Picky Eating and ARFID: What the Latest Research Tells Parents

 

  

A few days ago I read a comment from the parent of an autistic teenager that perfectly illustrates why we should never assume that a restricted diet is permanent.

Six years ago, their son ate only a handful of foods. Every meal was a battle. Introducing anything new seemed impossible. Family meals revolved around avoiding conflict, and eating outside the home was stressful for everyone.

Today, that same young man eats what most people would consider a perfectly normal adult diet. Vegetables, fish, different cuisines and healthy foods that once seemed unimaginable are now part of everyday life.

Nothing miraculous happened.

There was no breakthrough drug.

There was no secret supplement.

There were simply six years of patient, structured work by parents who refused to believe that their child's beige diet was fixed forever.

The journey was not easy. There were setbacks, disappointments and many failed attempts. Progress was measured in months and years rather than days and weeks.

But they never stopped trying.

Their story reminds us of something that is easy to forget. Today's diet does not have to be tomorrow's diet

That message is particularly timely because a major randomized clinical trial from Stanford University has just provided the strongest evidence yet that parents themselves can play a central role in helping children with ARFID make meaningful progress.

 

Three Messages I Hope Every Parent Remembers

If you read nothing else in this article, I hope you remember these three ideas.

 

First, ARFID is an observation, not an explanation.

It describes a child's eating behaviour, but it does not explain why that behaviour exists.

 

Second, ARFID is a diagnosis, not a prognosis.

Receiving the diagnosis tells you where your child is today. It says very little about where they could be five years from now.

 

Third, parents are not passive observers.

The strongest clinical evidence we now have suggests that parents are one of the most important parts of the treatment.

These three ideas underpin everything that follows.

 

ARFID Is a Diagnosis, Not a Prognosis

Avoidant Restrictive Food Intake Disorder (ARFID) was only added to the Diagnostic and Statistical Manual (DSM-5) in 2013. Before then, many children were simply described as "extremely picky eaters."

The diagnosis has been helpful because it acknowledges that severe food restriction is a genuine medical and psychological problem rather than simply bad behaviour or poor parenting.

However, diagnoses can sometimes have unintended consequences.

Some parents hear the word ARFID and begin to think that their child's eating habits are largely fixed.

That is understandable, but it is not what the diagnosis means.

ARFID tells us that eating has become sufficiently restricted to affect health, growth or everyday life.

It does not tell us why.

Nor does it tell us what the future holds.

In medicine we often confuse diagnosis with prognosis.

The two are completely different.

A diagnosis describes today's problem.

A prognosis attempts to predict tomorrow.

The Stanford study—and many individual family experiences—suggest that today's eating habits should not be viewed as a reliable predictor of where a child may be after several years of appropriate intervention.

 

Why Expectations Matter

One lesson I have learned from writing this blog is that expectations matter.

Not because optimism magically changes biology, but because expectations influence how much effort people are prepared to invest.

Autism provides many examples.

Poor handwriting is extremely common. Motor planning, muscle control and coordination are often affected.

Yet many autistic children spend years practising handwriting and eventually develop neat, legible writing. The neurological differences have not disappeared. The skill has improved.

Toilet training provides another example.

Some autistic children remain in diapers/nappies or pull-ups for years because everyone assumes they simply are not ready.

Other families invest months—or sometimes years—using structured toilet-training programs.

Not every child achieves complete independence or perfect handwriting.

But many achieve far more than anyone initially thought possible.

Eating should be viewed in exactly the same way.

It is another developmental skill.

Some children acquire it naturally.

Others require hundreds or even thousands of opportunities to practise.

Of course, families differ enormously.

Parents working full-time, caring for several children or home-schooling may genuinely struggle to devote the time required for intensive feeding programmes.

Those constraints are real and deserve understanding.

However, where circumstances allow, an ARFID diagnosis should encourage parents to increase their efforts—not reduce their expectations.

The diagnosis should increase expectations for intervention, not lower expectations for progress.

 

How Common Are Picky Eating and ARFID?

Picky eating is almost a normal part of childhood.

Around one quarter of young children go through a period when they refuse many foods. Fortunately, most gradually grow out of it.

Autism is different. Depending on the study, between 46% and nearly 90% of autistic children show significant food selectivity.

For some children this simply means having a short list of preferred foods.

For others, eating becomes so restricted that nutritional deficiencies develop, weight falters or everyday family life becomes dominated by food.

This is where ARFID begins.

Rather than being a completely separate condition, it is often helpful to think of ARFID as representing the severe end of a spectrum.

Normal childhood picky eating lies at one end.

Severe nutritional compromise lies at the other.

 

ARFID Is an Observation, Not an Explanation

Perhaps the most important question parents should ask is not:

"Does my child have ARFID?"

Instead ask:

"Why does my child have ARFID?"

The diagnosis simply tells us what is happening.

It does not explain why.

In autistic children there are often multiple contributing factors.

Some children have genuine sensory hypersensitivity.

Textures that seem perfectly ordinary to us may feel intensely unpleasant to them.

Others have chronic gastrointestinal discomfort.

Reflux, constipation, delayed stomach emptying and eosinophilic esophagitis can all make eating uncomfortable.

If every meal is associated with discomfort, avoiding food becomes entirely understandable.

Children with connective tissue disorders such as hypermobile Ehlers-Danlos syndrome, or milder extracellular matrix abnormalities, may also develop gastrointestinal dysmotility, reflux and abdominal pain. These conditions are increasingly recognised in autism and may contribute to restricted eating in a subgroup of children.

Oral-motor difficulties are another overlooked cause.

Some children struggle to chew particular textures efficiently, making certain foods genuinely difficult rather than simply disliked.

Anxiety also plays an important role.

A frightening choking episode or severe vomiting illness can lead to persistent fear of eating.

Finally, nutritional deficiencies themselves may worsen the problem.

Iron deficiency, zinc deficiency and other micronutrient deficiencies can alter taste perception, appetite and energy levels, creating a vicious cycle in which poor diet perpetuates itself.

The important message is this:

Finding one of these biological problems does not mean behavioural therapy is unnecessary.

It means behavioural therapy is more likely to succeed once the underlying problem is treated.

Medical treatment and feeding therapy should not be viewed as competing approaches.

In many children they complement one another.

 

Has modern food made ARFID more common?

One question that is rarely discussed is whether modern food itself may unintentionally reinforce food selectivity.

Many processed foods are engineered to be identical every single time.

Every chip/crisp tastes the same.

Every chicken nugget has the same texture.

Every biscuit/cookie feels identical.

Fresh food is completely different.

One strawberry is sweeter than the next.

One apple is crisp while another is soft.

Even two bananas picked from the same bunch taste slightly different.

For children who crave predictability, processed foods offer exactly that.

Nature does not.

This raises an interesting possibility.

Could a highly processed diet make it even harder for some children to accept the natural variability of real food?

We do not yet know the answer.

But it is certainly an area worthy of research.

 

Why dietary diversity matters

The goal of feeding therapy is not simply to make the list of accepted foods longer.

The goal is to improve health.

A child who expands their diet from five processed beige foods to ten processed beige foods has certainly made progress—but probably not enough.

The greatest benefits come from gradually introducing foods that provide nutrients missing from the existing diet.

Vegetables.

Fruit.

Fish.

Legumes.

Nuts.

Seeds.

Fermented foods.

Whole grains.

Each contributes something different.

Dietary diversity also feeds the gut microbiome.

Different bacteria thrive on different fibres and plant compounds. A monotonous diet supports a relatively monotonous microbiome.

Every additional plant food potentially feeds different bacterial species.

Given the growing evidence linking the gut microbiome to immune function, gastrointestinal health and possibly even brain function, this may become one of the most important long-term benefits of improving diet.

For autistic children, a broader diet may improve growth, bone health, immune function, gastrointestinal health and reduce nutritional deficiencies.

The goal is not simply to produce a child who eats more foods.

The goal is to produce a healthier child.

 

When does ARFID become dangerous?

Not every child who is a picky eater has ARFID.

Many children survive for years on a limited selection of foods and continue to grow normally. Although parents understandably worry, these children often improve naturally as they get older.

ARFID becomes a medical disorder when food restriction begins to cause significant problems. These may include:

  • Poor weight gain or weight loss
  • Slowed growth
  • Nutritional deficiencies (iron, zinc, vitamin D, vitamin C and others)
  • Dependence on nutritional supplements or tube feeding
  • Extreme anxiety surrounding meals
  • Family life becoming dominated by food

The distinction is important because the goal is not to pathologize every fussy eater. It is to identify children whose restricted eating is affecting their health or development.

Fortunately, even severe ARFID is treatable.

 

The Stanford Randomized Trial

The best evidence to date comes from researchers at Stanford University, who recently completed the first large randomized controlled trial of a treatment called ARFID Parent Training Protocol (ARFID-PTP).

Rather than providing months of intensive therapy directly to the child, the researchers trained parents.

This is a subtle but important shift.

Instead of trying to change the child during a one-hour therapy session each week, parents learn how to create hundreds of learning opportunities during normal family life.

The study involved 105 children aged 5–12 years with ARFID.

Families were randomly assigned either to receive the parent-training programme or to continue with usual care.

After six months, the differences were striking.

Children whose parents received the training accepted significantly more new foods, had fewer ARFID symptoms and were more likely to no longer meet diagnostic criteria for ARFID.

Perhaps even more impressive was that parents themselves became more confident and less anxious about feeding.

The therapy had changed not only children's behaviour but also the behaviour of the adults supporting them.

That may be one reason it worked so well.

 

The Therapist Becomes the Coach

Traditionally we imagine therapy as something that happens inside a clinic.

A therapist works with a child while parents wait outside.

Feeding therapy is different.

The therapist's real job is often to coach the parents.

Parents are present at breakfast.

Parents are present at lunch.

Parents are present at dinner.

That means they have thousands of opportunities each year to reinforce progress.

A therapist may only have fifty hours with a child over an entire year.

Parents may have over one thousand mealtimes.

Once parents understand the principles, they become the treatment.

The Stanford study confirms what many experienced feeding therapists have believed for years: empowering parents may be one of the most effective interventions available. 


Two treatments help ARFID, a common pediatric eating disorder, Stanford Medicine trial shows


Family vs Individual Treatment for Children With Avoidant/Restrictive Food Intake Disorder: A Randomized Clinical Trial

To examine the comparative efficacy of Family-based Treatment for Avoidant/Restrictive Food Intake Disorder (FBT-ARFID) to individual Psychoeducational Motivational Therapy (PMT) for underweight children with ARFID between the ages of 6 and 12 years of age. The main outcome evaluated was the difference between groups on change in percent estimated body weight (%EBW) from baseline (BL) to end of treatment (EOT).

Method

Ninety-eight children with ARFID were randomized to 14 sessions over 4 months of telehealth FBT-ARFID or PMT. Assessments of weight/height, eating-related cognitions, and behaviors associated with ARFID were collected online at BL, 1 month, 2 months, and EOT by assessors masked to treatment condition.

Results

FBT-ARFID was superior to PMT at the EOT in promoting increased %EBW. There were no differences between groups on improvements in overall severity of ARFID symptoms or other related ARFID symptoms; however, BL severity of ARFID symptoms moderated the effect, with children who were most symptomatic improving significantly more in FBT-ARFID than in PMT (exploratory analyses).

Conclusion

FBT-ARFID is superior to PMT for promoting weight gain in low-weight children with ARFID, especially for those children with greater severity of ARFID symptoms.

 

 

What Feeding Therapy Actually Involves

Many people imagine feeding therapy consists of persuading a child to eat vegetables.

In reality, it is usually much more gradual.

A child may first learn simply to tolerate a new food on the table.

Next they might touch it.

Then smell it.

Then lick it.

Eventually they may hold it in their mouth before spitting it out.

Only much later do they swallow it.

Each of these tiny steps represents progress.

Therapists often describe this as systematic desensitisation.

The child slowly learns that new foods are safe.

Repeated exposure gradually reduces anxiety.

The process resembles treatment for phobias.

Nobody expects someone with a fear of spiders to begin by holding a tarantula.

Instead, they gradually become comfortable with increasingly challenging situations.

Eating works in much the same way.

 

Why repeated exposure changes the brain

Parents often become discouraged after offering a new food ten or twenty times without success.

Unfortunately, that may not be nearly enough.

Research on food acceptance suggests that some children need dozens—or even hundreds—of exposures before a new food becomes familiar.

Every successful exposure teaches the brain something important:

"Nothing bad happened."

Over time, anxiety decreases.

Novelty decreases.

The food becomes part of the child's "safe" repertoire.

This is why consistency matters so much.

Small gains repeated hundreds of times eventually become major changes.

The six-year success story that opened this article probably consisted of thousands of tiny victories that, on their own, hardly seemed worth celebrating.

Together, they transformed a life.

 

Case histories teach us what clinical trials cannot

Clinical trials tell us what usually happens.

Individual families remind us what is possible.

The parent whose story inspired this article did not achieve success in six weeks.

They achieved it in six years.

That distinction matters.

Modern medicine often expects rapid results.

Parents understandably hope that one supplement, one therapy or one new technique will produce dramatic improvements within a few months.

Development rarely works that way.

Children learn through repetition.

Brains change through repetition.

Skills improve through repetition.

Eating is no different.

Some children will improve quickly.

Others will take years.

The important thing is that progress remains possible.

 

Progress Is Measured in Years

One reason families abandon feeding programmes is that they judge progress too soon.

Imagine expecting a child to learn the piano after six lessons.

Or expecting fluent reading after one month at school.

We would never make those assumptions.

Yet many people expect eating habits to change within weeks.

Instead, it is more realistic to ask:

"Is my child eating more different foods this year than last year?"

That question shifts the focus away from daily frustrations and towards long-term development.

The family who achieved success over six years almost certainly experienced long periods where nothing appeared to change.

But change was happening.

It was simply happening slowly.

 

Conclusion

Reading the six-year success story and then reading the Stanford trial left me with the same conclusion.

Parents matter.

Not because they caused ARFID.

Not because they are expected to fix it overnight.

But because they are uniquely placed to help their child improve every single day.

An ARFID diagnosis should never be interpreted as a prediction of lifelong eating difficulties.

Instead, it should be viewed as the starting point for understanding why eating has become difficult and for developing a structured plan to improve it.

For some children, that means treating reflux, constipation or nutritional deficiencies.

For others, it means addressing anxiety or oral-motor problems.

For almost all children, it means creating repeated opportunities to experience new foods without fear.

The therapist may design the programme.

The doctor may identify underlying medical problems.

But it is parents who provide the thousands of moments in which change actually happens.

As the family who inspired this article discovered, those moments accumulate.

One new food becomes two.

Two become ten.

Ten become a varied and healthy diet.

It may take years.

There will almost certainly be setbacks.

Progress may be frustratingly slow.

An eight-year-old with a poor diet and sloppy handwriting can become a teenager with a healthy diet and neat handwriting. Much depends on empowering parents with the knowledge, confidence and practical strategies to guide that journey.

As you embark on that journey, choose your community wisely. Social media can be an invaluable source of shared experience, but it can also become an echo chamber of low expectations. Look for communities that acknowledge today's challenges while continuing to believe in tomorrow's possibilities. Surround yourself with people who encourage evidence-based action, persistence and hope, rather than resignation.

Today's restricted eater does not have to remain tomorrow's restricted eater.




Thursday, 29 January 2026

Telmisartan as a useful biological “nudge-therapy,” particularly in bumetanide-responsive autism

 


A nudge is usually better than the sledgehammer !

 

Today’s post is another one most appropriate for people living in autism treatment-friendly counties (Russia, Ukraine, India, USA, Italy, Poland etc). Others will likely see this as from an alternative reality! The post is a bit long, just skip through it. 

My trial dose continues to be 20mg in a 65kg person. Doses trialed in schizophrenia have been much higher. Low doses are always the safest.

The post started life not as a review of any peer-reviewed clinical trials, but rather as an observational report, showing that revisiting the basic science can pay off. I made my initial review several years ago for my own purposes, but shared it in my blog.

I see that in fact the research has partially caught up:

Feinstein Institutes’ scientists find common blood pressure drug could be beneficial in some cases of autism

Scientists at Northwell Health’s Feinstein Institutes for Medical Research have made a significant discovery in autism spectrum disorder (ASD): a widely used blood pressure medication, captopril, can restore healthy function to the brain’s immune cells and reverse ASD-like behaviors in a preclinical animal model. This invaluable research focuses on a specific type of ASD believed to be triggered by a mother’s immune system during pregnancy, and could better understand autism and autism-like symptoms.

 

The full paper is here: 

Captopril restores microglial homeostasis and reverses ASD-like phenotype in a model of ASD induced by exposure in utero to anti-caspr2 IgG

 

What this now means - research from 2025 supports Peter’s 2017 idea to use telmisartan for autism

In 2025, researchers at the Feinstein Institutes for Medical Research published a preclinical study showing that modulation of the brain’s renin–angiotensin system (RAS) can reverse autism-like features in a specific immune-primed mouse model. In this model, prenatal immune exposure led to persistent microglial activation, synaptic abnormalities, and altered social behavior — changes that were significantly improved by treatment with captopril, an ACE inhibitor capable of crossing the blood–brain barrier.

Importantly, the study demonstrated that central (brain) RAS signaling is biologically relevant to neurodevelopmental plasticity, and that immune-driven alterations are not necessarily fixed. The benefit was not seen with ACE inhibitors lacking brain penetration, highlighting the importance of central rather than purely peripheral effects.

While captopril was used as a proof-of-concept tool, the underlying mechanism strongly supports the rationale for angiotensin receptor blockers (ARBs) — particularly telmisartan — which offer several advantages. Telmisartan directly blocks AT1 receptors, preserves potentially beneficial AT2 signaling, has a long half-life, and exerts additional anti-inflammatory, metabolic, and mitochondrial effects that are highly relevant to common autism subtypes involving neuroinflammation, behavioral rigidity, fatigue, and impaired stress resilience.

Thus, although the 2025 study does not establish a clinical treatment for autism, it independently validates the systems-level reasoning behind using telmisartan as a chronic “nudge” therapy in carefully selected autism phenotypes. The research supports the mechanism Peter proposed years earlier: that gently modulating regulatory systems such as the brain RAS can restore function in plastic but dysregulated neurodevelopmental circuits.

 

The keep it simple approach

I set out a very simple of framework of classic (Level 3) autism many years ago in this blog. It is also in my book and some presentations.

 

Today’s post falls in to the “central hormonal dysfunction” category.

Renin and angiotensin are both hormones

For the brain, angiotensin (especially angiotensin II) is the one that really matters. Renin is mostly just the upstream trigger.

The brain has its own local renin–angiotensin system, partly independent of the circulating one.

 

A recap for the science lovers - Angiotensin II in the brain

Angiotensin II is the active signalling molecule that actually does things in neural tissue:

  • Acts as a neuromodulator
  • Shapes excitatory–inhibitory balance
  • Influences dopamine, GABA, glutamate
  • Regulates stress, threat detection, motivation
  • Affects neuroinflammation, oxidative stress
  • Alters plasticity and myelination

All of that happens via angiotensin receptors, mainly AT1 and AT2.

 

In the brain, which receptor is activated matters more than how much angiotensin is around:

AT1 receptor (problematic when dominant)

  • Increases stress signalling
  • Promotes neuroinflammation
  • Increases sympathetic tone
  • Worsens cognitive rigidity

AT2 receptor (generally protective)

  • Promotes neurite growth
  • Supports learning and repair
  • Anti-inflammatory
  • Pro-plasticity

This is why ARBs (especially telmisartan) are interesting neurologically:

  • They block AT1
  • They shunt signalling toward AT2
  • They act inside the brain, not just on blood pressure

 

Back to the more readable stuff

When treating broader autism you can consider the 150-200 possible therapies as ranging from small nudges in the right direction, to a precise hit with a mallet that corrects a precise dysfunction (a specific ion channel dysfunction, a lack of folate in the brain) to a sledge hammer that affects the entire brain (potassium bromide, as an example).

If you have epilepsy and severe aggression then a sledgehammer may well be what you need.

When I first trialed Telmisartan many years ago, I saw that it had an immediate effect, but back then I did not see it as being big enough. It certainly was a nudge, but I was still looking for that mallet, or indeed a sledgehammer. So I moved on.

Last year I revisited Telmisartan and now it is a core therapy. I am happy to include nudge therapies.  

If you have mild autism then a nudge or two maybe all that you need to overcome troubling issues.

If you follow my polytherapy approach for severe autism, then you might select a few nudge therapies and some stronger ones to create a personalized optimization.

 

Telmisartan

Telmisartan is an ARB (angiotensin II type-1 receptor blocker) commonly used to lower blood pressure. But, Telmisartan is thought of best understood not as a single-target drug, but as a system-level regulator.

Telmisartan is highly fat soluble (lipophilic) so it can penetrate the brain and even your bones. Bones matter for old people and all people with level 3 autism.  

Bones are a weak point in severe autism due to the side effects of drugs commonly used, poor diet, lack of exercise and specific genetic issues (in some monogenic autisms).

Bone is not inert. It has active RAAS signalling, telmisartan reaches bone tissue and blocks local AT₁ signalling, reduces inflammatory and oxidative tone in bone microenvironments. Via PPAR-γ, can influence osteoblast/osteoclast balance improving bone density

So an unexpected nudge towards stronger bones. 

The core actions

  • AT₁ receptor blockade (RAAS modulation)
    Reduces chronic angiotensin II signalling, lowering background stress, sympathetic drive, and neurovascular strain.
  • PPAR-γ partial agonism
    Improves metabolic efficiency, mitochondrial function, and lipid–glucose handling; contributes to anti-inflammatory effects.
  • Autonomic calming
    Lowers sympathetic tone and stress reactivity without sedation. This a nudge effect towards better sleep, in some people
  • Anti-inflammatory and antioxidant effects
    Indirectly reduces microglial activation and oxidative stress signalling. Microglia are the brain’s immune cells and can be in state of constant activation, which blocks them doing their basic housekeeping duties.
  • Neurovascular effects
    Improves cerebral blood flow regulation and oxygen–nutrient delivery. In many types of severe autism, and also in dementia, the brain is unable to produce enough fuel (ATP). While there are many possible factors involved a key one is delivery of glucose and oxygen from your blood.

 

Indirect downstream effects (relevant to neurodevelopment)

  • Improved cellular energy status
    Supports ion-pump function and transporter regulation. This is a nudge by improving the environment, Telmisartan does not force the ion-pumps directly
  • Stabilisation of chloride homeostasis (indirect)
    Biases the NKCC1–KCC2 balance toward better chloride extrusion in vulnerable circuits, without forcing a gradient shift.

This is the big plus for bumetanide responders

Neuronal chloride levels are set by the balance between NKCC1 (chloride import) and KCC2 (chloride extrusion).

In some with autism the GABA development switch failed to activate after birth and so NKCC1 is overexpressed and KCC2 is under expressed

Stress, inflammation, and high activity increase NKCC1 influence and chloride loading.

KCC2 function is energy- and redox-dependent, and degrades under metabolic strain.

Telmisartan does not directly block NKCC1 or activate KCC2.

By reducing RAAS-driven stress signalling, it lowers pressure toward chloride accumulation.

Improved metabolic and redox conditions stabilise KCC2 membrane function.

Reduced autonomic overdrive lowers activity-dependent chloride loading.

The net effect is a bias toward more reliable chloride extrusion in vulnerable circuits.

This stabilises inhibition without forcing a chloride gradient shift, which KBr the sledgehammer would do. 

  • Reduced excitability pressure
    Lowers the likelihood that inhibitory signalling becomes destabilised under stress.

 

Theoretical functional consequences (when it works)

  • Lower baseline arousal and irritability
  • Improved mood stability
  • Increased behavioural flexibility
  • Greater tolerance of sensory and cognitive load
  • Enhanced availability for learning and interaction

 

My experience

When I conducted my review of “all autism” several years ago I did look at angiotensin. It looked to me that Telmisartan ticked many of the boxes for a cheap generic drug that could be repurposed for autism.

I did trial it and noted an immediate mood improvement with the strange effect of making Monty want to sing.

Several years later trialing it again. Again mood improved, there was no singing, but there was a desire to dance.

It also makes him less rigid. The best example is that when he empties the dishwasher he very clearly now puts things back in different places. You could argue this is negative, or you could see that as expressing his will rather than robotically following a pattern. More on that in the basal ganglia section.


The Basal Ganglia

The basal ganglia is the part of the brain that drives conditions like Tourette syndrome and PANS-PANDAS.

In PANS-PANDAS the immune system temporarily hijacks basal ganglia signalling. This is reversable, with prompt treatment.

The basal ganglia do not generate behaviour.

They gate behaviour.

When basal ganglia inhibition is stable:

  • unwanted actions are quietly suppressed  (no tics)
  • chosen actions feel voluntary
  • habits can be overridden (no autistic rigidity)
  • novelty is possible (try new foods, or watch a different cartoon) 

When basal ganglia function is disrupted (by genetics, inflammation, chloride instability, dopamine imbalance, Purkinje cell loss):

  • the repertoire of behaviours is still there
  • the motor programs still exist
  • the thoughts still arise

What is lost is control over which ones fire. This manifest in autism as

Rigidity and stereotypies

  • Repetitive behaviours are not “added”
  • They become locked in
  • Alternative actions cannot pass the gate

The system defaults to what feels safe and known.

This links to 2 further subjects of interest:

·        Purkinje cell loss in severe autism
·        ARFID (Avoidant/Restrictive Food Intake Disorder)

 

Purkinje cell loss as one possible driver of basal ganglia dysfunction

Purkinje cells are the very large, energy-intensive output neurons of the cerebellar cortex, providing continuous inhibitory timing signals to the deep cerebellar nuclei.

During the first two years of life, rapid brain growth creates extreme ATP demand, and transient mitochondrial or metabolic shortfalls can cause brief “power outages.” Because Purkinje cells are among the largest and most metabolically demanding neurons, they are selectively vulnerable and may be lost early, in a patchy and permanent manner. This a classic finding in port-mortem brain studies of people who had severe autism.

Purkinje cell loss leads to clumsiness and dyspraxia, because the cerebellum’s output signal loses timing precision, causing movements to be poorly planned, sequenced, and adjusted despite normal muscle strength. It does not lead to paralysis.

The resulting noisy cerebellar output propagates via thalamocortical loops to the basal ganglia, where it destabilizes action-selection and gating, particularly in the context of immature chloride regulation and weakened GABAergic inhibition.

Although the original cerebellar injury cannot be reversed, downstream circuits remain plastic, allowing pharmacological “nudges” such as bumetanide, atorvastatin, and telmisartan to partially restore inhibitory precision, improve basal ganglia gating, and reopen a window of motor-cognitive flexibility.

 

ARFID (Avoidant/Restrictive Food Intake Disorder)

ARFID can be the feeding expression of the same underlying circuit problem.

The framework explains ARFID extremely well, especially the autism-associated form of ARFID. In fact, it explains it better than sensory-only models. 

ARFID through the basal ganglia “gate” lens

Repetitive behaviours are not added — they become locked in.
Alternative actions cannot pass the gate.
The system defaults to what feels safe and known.

That description fits ARFID almost perfectly. 

In autism and related neuroimmune states, ARFID often acts as a behavioural marker of basal ganglia gating dysfunction, reflecting loss of choice rather than loss of appetite.

ARFID is not always basal ganglia–driven.

There are other ARFID subtypes:

  • trauma-based (choking/vomiting)
  • primary sensory aversion
  • gastrointestinal pain–avoidance
  • appetite dysregulation from meds or illness

But in autism-associated ARFID, especially when it:

  • fluctuates with stress or illness
  • coexists with rigidity, tics, OCD traits
  • improves alongside mood and flexibility

the basal ganglia model fits extremely well. 

Blunt pharmaceutical treatment (sledgehammer) of ARFID does not work. Nudges seem a better choice. Nudges can be behavioral, or biological. 

Beyond telmisartan, the most promising pharmaceutical nudges for ARFID are likely those that reduce immune and autonomic stress on basal ganglia circuits while preserving motivation and behavioural flexibility, rather than suppressing output.

Many autism interventions provide a nudge to better functioning of the basal ganglia (NAC, ALA, low dose clonidine, atorvastatin etc).

Indeed one notable immediate effect of atorvastatin on Monty 14 years ago, was that he starting to come downstairs from his bedroom by himself, and not get “stuck” at the top of the stairs awaiting instructions.

I used to call this cognitive inhibition, but perhaps the gating model explains it better.

 

What the behaviour actually shows

“Stuck at the top of the stairs awaiting instructions”
is not a strength or balance problem.

It reflects:

  • failure of self-initiated action
  • dependence on external cueing (prompt dependence, in ABA terminology)
  • intact ability, but blocked execution

That already points away from motor cortex and toward action-selection systems.

 

Basal ganglia explanation

Basal ganglia = action gating, not movement generation

The basal ganglia decide:

  • when an action is allowed to start
  • whether it is safe to proceed without prompting

In autism (and related neuroimmune states), this gate can become over-conservative:

  • “wait”
  • “don’t move”
  • “need instruction”

So the child:

  • knows how to go downstairs
  • but cannot release the action independently

 

Why stairs are a perfect stress test

Descending stairs requires:

  • motor sequencing
  • balance prediction
  • suppression of fear/uncertainty
  • confidence in outcome

Basal ganglia dysfunction often shows up first in:

  • transitions
  • initiation
  • descending movements
  • unprompted actions

So “stuck at the top of the stairs” is a classic gating failure.

 

Why atorvastatin could change this quickly

Atorvastatin did not:

  • teach a new skill
  • strengthen muscles
  • improve coordination

What it plausibly did was reduce a state constraint.

Immune / inflammatory relief

If there was:

  • low-grade neuroinflammation
  • immune-driven basal ganglia noise

Then dampening that can:

  • lower threat signalling
  • stabilise dopamine–GABA balance
  • relax excessive inhibitory gating

When that happens:

actions that were already available suddenly “go.”

That can be rapid.

 

Reduced “protective inhibition”

In stressed systems, the brain sometimes actively prevents independence:

  • to avoid risk
  • to avoid uncertainty

Once the stress signal drops, the system stops applying the brake.

This feels like:

  • confidence
  • initiative
  • independence

 

Why instruction dependence disappears

Needing instruction is a workaround:

  • the external cue substitutes for internal gating
  • the basal ganglia borrow cortical direction

When gating improves:

  • the workaround is no longer needed
  • behaviour becomes self-initiated

This is not just basal ganglia

Other systems likely contributed:

Cerebellum

  • prediction of movement outcome
  • timing and sequencing
  • fear of misstep

Cerebellar function improves when:

  • inflammation drops
  • prediction error decreases

Autonomic system

  • high sympathetic tone increases “freeze”
  • calming allows movement initiation

Confidence loop

  • once one successful descent occurs
  • future attempts are easier
  • habit loop updates

But the gatekeeper is still basal ganglia.

 

Conclusion

The basal ganglia are not “movement centres” in the simple sense.
They are action–selection and state–selection systems.

They decide:

  • which action to initiate
  • when to initiate it
  • whether to repeat the same pattern or explore a new one
  • how much reward, pleasure, and motivation is attached to action

They sit at the junction of:

  • movement
  • mood
  • motivation
  • habit
  • flexibility

That is why basal ganglia changes show up as movement + emotion + novelty, all together.

 

Basal ganglia are especially sensitive in autism

Basal ganglia circuits:

  • are GABA-heavy
  • are chloride-sensitive
  • rely on finely balanced inhibition
  • are vulnerable to stress, inflammation, and metabolic strain

When inhibition in these circuits is unstable:

  • action initiation becomes effortful
  • behaviour becomes repetitive and rigid
  • novelty feels unsafe
  • mood flattens or becomes anxious

What changed biologically (without forcing anything)

When inhibition becomes more reliable (not stronger, just more predictable):

  • neurons fire when they should, not erratically
  • “gating” improves and actions can pass through more smoothly
  • reward signals are no longer drowned out by noise

 

Why did Monty become happier

Mood is not just cortical thought, it is basal ganglia tone.

With better inhibitory stability:

  • dopamine signalling becomes cleaner
  • reward prediction improves
  • the background “threat” signal drops

The result is:

  • spontaneous positive affect
  • relaxed facial expression
  • joy without obvious cause

This is state change, not learned happiness.

 

Why the urge to dance appears

Dancing is a near-perfect basal ganglia readout.

It requires:

  • effortless movement initiation
  • rhythmic pattern generation
  • reward linked directly to motion

When basal ganglia output is constrained:

  • movement feels heavy
  • initiation is delayed
  • spontaneous rhythm disappears

When the constraint lifts:

  • movement becomes intrinsically rewarding
  • the body “wants” to move
  • rhythm emerges without instruction

That is why dancing appears before language or cognition improves.

 

Why he emptied the dishwasher differently

Changing how a familiar task is done means:

  • the brain is no longer locked into a single motor–habit template
  • alternative action sequences are now selectable
  • exploration feels safe

This is classic basal ganglia flexibility.

Nothing taught him that new method.

The system simply allowed another option to pass through the gate.